2021 Revenues ($USD) : $3,206,900,947 2021 Revenues (foreign currencies) : JP¥352,246,000,000 2021 R&D spend : $525,118,354 2021 Number of Employees : 5,752 Fiscal Year End : 12/31/2021 Leader : CEO Masashi Miyamoto
[Image courtesy of Kyowa Kirin]
The Tokyo-headquartered pharmaceutical and biotechnology firm focuses on developing drugs in oncology, nephrology, central nervous system and immunology. Focus areas for its drug discovery efforts include therapeutic antibodies, small molecule drugs, nucleic acid drugs and regenerative medicine. Central products include anemia treatments ESPO and Nesp — as well as G-Lasta, a sustained duration form of granulocyte colony-stimulating factor product of chemotherapy-induced neutropenia. —BB
Tell Us What You Think!
You must be logged in to post a comment.